Bajaj Healthcare's shares are currently trading at RS. 679.35, up by 22.95 points (3.50%) from its previous closing price of RS. 656.40 on the BSE. The stock opened at RS. 648.95, hitting a high of RS. 681.40 and a low of RS. 639.55 so far. A total of 52,670 shares have been traded on the counter.

The BSE Group 'B' stock, with a face value of RS. 5, reached a 52-week high of RS. 689.95 on January 20, 2025, and a 52-week low of RS. 265.00 on June 4, 2024. Over the past week, the stock has traded between a high of RS. 689.00 and a low of RS. 510.00. The company’s current market capitalization stands at RS. 2101.23 crore.

Promoters hold 59.19% of the company's shares, while institutional and non-institutional investors own 3.37% and 37.45%, respectively.

Approval for New Drug Manufacturing

Bajaj Healthcare has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and drug formulation of Pimavanserin (34 mg capsule). This atypical antipsychotic is used for treating hallucinations and delusions associated with Parkinson’s disease psychosis.

Pimavanserin, marketed globally under the brand name NUPLAZID, has become a preferred treatment in the US antipsychotic segment. Recently, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is expected to generate over $1 billion in net sales in 2025.

Bajaj Healthcare has also extended its offer for Pimavanserin to several leading Indian pharmaceutical companies, ensuring its availability in the domestic market.

The company primarily focuses on the development, manufacturing, and supply of Amino Acids, Nutritional Supplements, and Active Pharmaceutical Ingredients (API) for the Pharmaceutical, Nutraceutical, and Food industries.